Media Center Investor Relations Overview Newsroom Press Releases Company Statements InBriefs Media Center Events Stock Information Stock Quote & Chart Analyst Coverage Ownership Profile Financials SEC Filings Annual Reports Governance Governance Documents Committee Composition Investor Resources Investor FAQs Settlement Information Contact Us Investor Email Alerts Investor contact760-603-2331Email Media contact760-603-4679Email Company Statements Oct 07, 2023 Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen Read More Oct 07, 2023 Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen Read More Jan 23, 2023 Ionis’ statement about the FDA advisory committee meeting on tofersen Read More
Oct 07, 2023 Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen Read More Oct 07, 2023 Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen Read More Jan 23, 2023 Ionis’ statement about the FDA advisory committee meeting on tofersen Read More
Oct 07, 2023 Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen Read More
Oct 07, 2023 Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen Read More
